Table 2.
Presence of Categorical Variables According to Thyroid Regulation Groups
| Variables |
N
|
Low PTFQI |
Combined median PTFQI |
High PTFQI |
p-Heter 5 groups |
p-Trend 3 groups |
||
|---|---|---|---|---|---|---|---|---|
| Primary subhypothyroidism |
Median PTFQI |
Primary subhyperthyroidism |
||||||
| |
|
% [n] |
% [n] |
% [n] |
% [n] |
% [n] |
|
|
| (N = 58) | (N = 71) | (N = 53) | (N = 59) | (N = 55) | ||||
| Type 2 diabetes | 296 | 13.8 [8] | 26.8 [19] | 24.5 [13] | 27.1 [16] | 41.8 [23] | ||
| 1.00 (Ref.) | 1.89 [0.76–5.09] | 1.58 [0.58–4.46] | 1.51 [0.58–4.19] | 2.88 [1.14–7.86] | 0.23 | 0.02 | ||
| Ischemic heart disease | 296 | 0.0 [0] | 8.5 [6] | 11.3 [6] | 15.3 [9] | 16.4 [9] | ||
| 1.00 (Ref.) | — | — | — | — | 0.03 | 0.04 | ||
| Atrial fibrillation | 296 | 1.7 [1] | 9.9 [7] | 7.5 [4] | 20.3 [12] | 21.8 [12] | ||
| 1.00 (Ref.) | 4.64 [0.72–91.99] | 3.73 [0.48–77.92] | 8.12 [1.33–157.86] | 8.13 [1.33–158.20] | 0.13 | 0.05 | ||
| Cerebrovascular disease | 296 | 3.4 [2] | 2.8 [2] | 11.3 [6] | 3.4 [2] | 14.5 [8] | ||
| 1.00 (Ref.) | 0.52 [0.06–4.67] | 2.38 [0.48–17.42] | 0.44 [0.05–3.98] | 2.21 [0.47–15.88] | 0.08 | 0.15 | ||
| COPD | 296 | 0.0 [0] | 0.0 [0] | 3.8 [2] | 6.8 [4] | 0.0 [0] | ||
| 1.00 (Ref.) | — | — | — | — | 0.02 | 0.81 | ||
| OSAS | 296 | 0.0 [0] | 5.6 [4] | 7.5 [4] | 8.5 [5] | 5.5 [3] | ||
| 1.00 (Ref.) | — | — | — | — | 0.10 | 0.23 | ||
| Hypertension (Exam BP ≥140/90) | 254 | 14.3 [6] | 28.6 [18] | 36.7 [18] | 38.9 [21] | 41.3 [19] | ||
| 1.00 (Ref.) | 2.27 [0.84–6.92] | 3.16 [1.14–9.78] | 2.99 [1.10–9.17] | 3.19 [1.14–9.94] | 0.16 | 0.05 | ||
| Obesity (Exam BMI ≥30 kg/m2) | 296 | 22.4 [13] | 36.6 [26] | 37.7 [20] | 28.8 [17] | 29.1 [16] | ||
| 1.00 (Ref.) | 1.82 [0.83–4.12] | 2.00 [0.87–4.73] | 1.32 [0.56–3.17] | 1.34 [0.55–3.28] | 0.45 | 0.51 | ||
| Overweight (Exam BMI ≥25 kg/m2) | 296 | 44.8 [26] | 59.2 [42] | 67.9 [36] | 57.6 [34] | 56.4 [31] | ||
| 1.00 (Ref.) | 1.60 [0.79–3.29] | 2.32 [1.07–5.18] | 1.37 [0.64–2.95] | 1.27 [0.59–2.78] | 0.29 | 0.50 | ||
| Dyslipidemiaa | 296 | 48.3 [28] | 57.7 [41] | 50.9 [27] | 49.2 [29] | 63.6 [35] | ||
| 1.00 (Ref.) | 1.10 [0.51–2.37] | 0.75 [0.33–1.69] | 0.53 [0.23–1.19] | 0.97 [0.42–2.23] | 0.36 | 0.99 | ||
| Hypertriglyceridemia (≥200 mg/dL) | 296 | 5.2 [3] | 14.1 [10] | 20.8 [11] | 3.4 [2] | 9.1 [5] | ||
| 1.00 (Ref.) | 2.92 [0.82–13.81] | 4.34 [1.23–20.41] | 0.52 [0.06–3.31] | 1.43 [0.32–7.50] | 0.01 | 0.73 | ||
| Hypoalbuminemia (≤3.5g/dL) | 296 | 3.4 [2] | 4.2 [3] | 1.9 [1] | 11.9 [7] | 18.2 [10] | ||
| 1.00 (Ref.) | 0.98 [0.15–7.73] | 0.43 [0.02–4.65] | 2.55 [0.55–18.17] | 4.11 [0.95–28.53] | 0.04 | 0.03 | ||
| AST ≥50 U/L | 293 | 3.5 [2] | 2.9 [2] | 1.9 [1] | 1.7 [1] | 7.3 [4] | ||
| 1.00 (Ref.) | 0.83 [0.10–7.23] | 0.58 [0.03–6.39] | 0.55 [0.02–6.30] | 2.62 [0.44–21.39] | 0.50 | 0.22 | ||
| ALT ≥50 U/L | 296 | 8.6 [5] | 5.6 [4] | 1.9 [1] | 0.0 [0] | 5.5 [3] | ||
| 1.00 (Ref.) | — | — | — | — | 0.07 | 0.44 | ||
| GGT ≥55 U/L | 260 | 13.0 [6] | 14.3 [9] | 9.8 [5] | 6.1 [3] | 29.4 [15] | ||
| 1.00 (Ref.) | 1.16 [0.38–3.73] | 0.73 [0.19–2.61] | 0.43 [0.08–1.78] | 2.73 [0.96–8.62] | 0.02 | 0.02 | ||
| LDH ≥248 U/L | 243 | 7.5 [3] | 6.8 [4] | 10.6 [5] | 8.5 [4] | 22.0 [11] | ||
| 1.00 (Ref.) | 0.85 [0.18–4.58] | 1.50 [0.34–7.82] | 1.22 [0.24–6.76] | 3.81 [1.02–18.68] | 0.11 | 0.02 | ||
Data are expressed in % [n]. OR [CI] from models adjusted for age and sex, referenced to the Low PTFQI group. p-Heter is the p-value for testing differences among groups. p-Trend is the p-value from a regression model that includes group as a numerical value.
a
Included being treated with lipid-lowering drugs.
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; GGT, gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase; OSAS, obstructive sleep apnea syndrome.